About Bio Nucleus Pharmaceuticals Private Limited
Data last updated:
Bio Nucleus Pharmaceuticals Private Limited is a private limited company based in New Delhi, Delhi, India. It operates in the pharmaceutical retail and distribution segment of the pharmaceuticals sector. It was incorporated on 19 January 2015 and has been in existence for over 11 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U33110DL2015PTC275677. Its GSTIN is 06AAGCB1568H1ZQ (Haryana).
The company has an authorised share capital of ₹1 Lakh and a paid-up capital of ₹1 Lakh. It is led by directors Supriya Verma and Kumar Prashant.
Its last annual general meeting (AGM) was held on 29 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at D – 2/144 Plot No – 144 Upper G/Floor Gali No – 3 Kh No – 720/590 Mahavir Enclav, E, New Delhi, Delhi, India – 110045.
As per the financials filed for FY 2024, the company reported a revenue of ₹2.06 Lakh, a decline of 91% compared to the previous year. For the same year it recorded a net loss of ₹85,446 (net margin -41.5%) and EBITDA of ₹1.85 Lakh (EBITDA margin 90%). Revenue has declined at a compounded annual rate (CAGR) of 73% over three years and 67% over five years.
Court records list 1 case involving the company, including 1 filed against it; 1 case is pending.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website bionucleuspharma.com.
Company details
Contact details
Bio Nucleus Pharmaceuticals Private Limited's registered office is in New Delhi, Delhi. Its website is bionucleuspharma.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressD – 2/144 Plot No – 144 Upper G/Floor Gali No – 3 Kh No – 720/590 Mahavir Enclav, E, New Delhi, Delhi, India – 110045
- IndustryPharma, Pharmaceutical Retailers & Distributors
To see the full contact details of Bio Nucleus Pharmaceuticals Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Financials of Bio Nucleus Pharmaceuticals Private Limited
FY 2025 filings availableBio Nucleus Pharmaceuticals Private Limited reported revenue of ₹2.06 Lakh (down 91% YoY) for FY 2024.
Compounded Annual Growth Rate (CAGR)
Revenue has declined at a compounded annual rate (CAGR) of 67% over five years, including a 91% fall in the latest year. EBITDA rose 142% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹1.85 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | -₹85,446 | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 90% | ||||
| Net Profit Margin | -41.5% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Bio Nucleus Pharmaceuticals Private Limited, buy the company report.
Board of directors of Bio Nucleus Pharmaceuticals Private Limited
Bio Nucleus Pharmaceuticals has 2 current directors and 7 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Supriya Verma | Director | 30 Sep 2021 | 5 Years 1 Months | Current |
| Kumar Prashant Also directs: Byder Solutions Private Limited | Director | 01 Feb 2018 | 8 Years 8 Months | Current |
Peer comparison
Bio Nucleus Pharmaceuticals Private Limited is compared with the 10 companies closest to it by revenue in the Pharma industry (Formulations, Pharmaceuticals), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Fiorallo Pharmaceuticals Private Limited | ₹2.07 Lakh (FY 2024) | -31.0% | Ghaziabad, Uttar Pradesh, India | |||
| Ady Advit Pharmaceuticals Private Limited | ₹2.07 Lakh (FY 2025) | -70.0% | Lucknow, Uttar Pradesh, India | |||
| Orgone Pharmaceuticals Private Limited | ₹2.07 Lakh (FY 2020) | 103.0% | Patna, Bihar, India | |||
| Cortex Pharmaceuticals and Medi Services Private Limited | ₹2.07 Lakh (FY 2025) | -36.0% | Surat, Gujarat, India | |||
| Calisto Developers Private Limited | ₹2.06 Lakh (FY 2024) | -99.0% | Jadcherla, Telangana, India | |||
| Bio Nucleus Pharmaceuticals Private Limitedthis company | ₹2.06 Lakh (FY 2024) | -₹85,446 | -41.5% | -91.0% | New Delhi, Delhi, India | |
| Insha Pharmaceuticals Private Limited | ₹2.06 Lakh (FY 2017) | 106.0% | Uttar Pradesh, India | |||
| Remmycare Pharmaceuticals Private Limited | ₹2.06 Lakh (FY 2025) | 1683.0% | Vadodara, Gujarat, India | |||
| Pearim Pharmaceuticals Private Limited | ₹2.06 Lakh (FY 2025) | -3.0% | Mumbai, Maharashtra, India | |||
| Primus Lifesciences Private Limited | ₹2.06 Lakh (FY 2024) | -35.0% | Bhopal, Madhya Pradesh, India | |||
| Zyshak Pharmaceuticals Private Limited | ₹2.06 Lakh (FY 2020) | -98.0% | Mumbai, Maharashtra, India |
To see the full peer comparison of Bio Nucleus Pharmaceuticals Private Limited, buy the company report.
Auditor
Bio Nucleus Pharmaceuticals Private Limited is audited by S NAYYAR & CO for the financial year 2018.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| S NAYYAR & CO | FY 2018 | 002439N |
Shareholding
The shareholding of Bio Nucleus Pharmaceuticals Private Limited is on record for 4 financial years, the latest being FY 2018, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|
| Promoters | ||||
| Domestic institutional investors (DII) | ||||
| Foreign institutional investors (FII) | ||||
| Public | ||||
| Others |
To see the full shareholding pattern of Bio Nucleus Pharmaceuticals Private Limited, buy the company report.
Legal cases
Bio Nucleus Pharmaceuticals Private Limited has 1 court case on record: 1 filed against it. All case is pending.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 1 | 1 | 1 |
Cases on record (1 of 1)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, South West, Delhi | Court case (CS DJ ADJ) | Filed against the company by an individual | Pending |
To see the full case history of Bio Nucleus Pharmaceuticals Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Bio Nucleus Pharmaceuticals Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Bio Nucleus Pharmaceuticals has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 06AAGCB1568H1ZQ | Haryana | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Bio Nucleus Pharmaceuticals Private Limited, buy the company report.
Recent activity
Bio Nucleus Pharmaceuticals Private Limited has 9 board changes on record since 2015: 2 appointments and 7 cessations. The latest: Supriya Verma ceased to be Additional Director on 30 Nov 2021.
Frequently asked questions
Bio Nucleus Pharmaceuticals is an active private limited company based in New Delhi, Delhi, India. The company works in pharmaceutical retailers and distributors, within the pharma industry. It was incorporated on 19 January 2015 (11+ years old) and is registered under CIN U33110DL2015PTC275677.
Bio Nucleus Pharmaceuticals has 2 current directors:
- Supriya Verma - Director
- Kumar Prashant - Director
The latest financial statements of Bio Nucleus Pharmaceuticals on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 29 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Bio Nucleus Pharmaceuticals is 06AAGCB1568H1ZQ, registered in Haryana.
The CIN (Corporate Identification Number) of Bio Nucleus Pharmaceuticals is U33110DL2015PTC275677. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Bio Nucleus Pharmaceuticals has 1 court case on record: 1 filed against it. 1 is pending.
Bio Nucleus Pharmaceuticals was incorporated on 19 January 2015, making it 11+ years old. It is registered with the Registrar of Companies, Delhi.
The peers of Bio Nucleus Pharmaceuticals by revenue are Fiorallo Pharmaceuticals Private Limited, Ady Advit Pharmaceuticals Private Limited, Orgone Pharmaceuticals Private Limited, Cortex Pharmaceuticals and Medi Services Private Limited, Calisto Developers Private Limited and 5 more, all in the Pharma industry (Formulations, Pharmaceuticals).
Supriya Verma ceased to be Additional Director on 30 Nov 2021. Rajiv Chhikara ceased to be Director on 08 Oct 2021. Supriya Verma was appointed as Director on 30 Sep 2021. Bio Nucleus Pharmaceuticals has 9 board changes on record in total.
Bio Nucleus Pharmaceuticals can be reached through the website bionucleuspharma.com. Its registered office is in New Delhi, Delhi, India.
The registered office of Bio Nucleus Pharmaceuticals is at D – 2144 Plot No – 144 Upper GFloor Gali No – 3 Kh No – 720590 Mahavir Enclav, E, New Delhi, Delhi, India – 110045.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
